Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 224

1.

Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition.

Naqash AR, Appah E, Yang LV, Muzaffar M, Marie MA, Mccallen JD, Macherla S, Liles D, Walker PR.

J Immunother Cancer. 2019 Jul 5;7(1):169. doi: 10.1186/s40425-019-0648-3.

2.

Harnessing Microglia and Macrophages for the Treatment of Glioblastoma.

Prionisti I, Bühler LH, Walker PR, Jolivet RB.

Front Pharmacol. 2019 Jun 5;10:506. doi: 10.3389/fphar.2019.00506. eCollection 2019. Review.

3.

Targeting self and neo-epitopes with a modular self-adjuvanting cancer vaccine.

Belnoue E, Mayol JF, Carboni S, Di Berardino Besson W, Dupuychaffray E, Nelde A, Stevanovic S, Santiago-Raber ML, Walker PR, Derouazi M.

JCI Insight. 2019 Apr 23;5. pii: 127305. doi: 10.1172/jci.insight.127305.

4.

Peptides as cancer vaccines.

Calvo Tardón M, Allard M, Dutoit V, Dietrich PY, Walker PR.

Curr Opin Pharmacol. 2019 Aug;47:20-26. doi: 10.1016/j.coph.2019.01.007. Epub 2019 Mar 1. Review.

PMID:
30831470
5.

Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients.

Migliorini D, Dutoit V, Allard M, Hallez NG, Marinari E, Widmer V, Philippin G, Corlazzoli F, Gustave R, Kreutzfeldt M, Blazek N, Wasem J, Hottinger A, Koka A, Momjian S, Lobrinus A, Merkler D, Vargas MI, Walker PR, Patrikidou A, Dietrich PY.

Neuro Oncol. 2019 Feb 12. doi: 10.1093/neuonc/noz040. [Epub ahead of print]

PMID:
30753611
6.

Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models.

Genoud V, Marinari E, Nikolaev SI, Castle JC, Bukur V, Dietrich PY, Okada H, Walker PR.

Oncoimmunology. 2018 Sep 5;7(12):e1501137. doi: 10.1080/2162402X.2018.1501137. eCollection 2018.

7.

Let there be oxygen and T cells.

Walker PR.

J Clin Invest. 2018 Nov 1;128(11):4761-4763. doi: 10.1172/JCI124305. Epub 2018 Oct 15.

8.

Stage III non-small cell lung cancer: escalation matters, but how?

Hegde AM, Walker PR.

Transl Lung Cancer Res. 2018 Apr;7(Suppl 2):S107-S110. doi: 10.21037/tlcr.2018.03.02. No abstract available.

9.

Mechanistic insights into the efficacy of cell penetrating peptide-based cancer vaccines.

Grau M, Walker PR, Derouazi M.

Cell Mol Life Sci. 2018 Aug;75(16):2887-2896. doi: 10.1007/s00018-018-2785-0. Epub 2018 Mar 5. Review.

10.

The survival benefit of neoadjuvant chemotherapy and pCR among patients with advanced stage triple negative breast cancer.

Biswas T, Efird JT, Prasad S, Jindal C, Walker PR.

Oncotarget. 2017 Nov 20;8(68):112712-112719. doi: 10.18632/oncotarget.22521. eCollection 2017 Dec 22.

11.

Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma.

Dutoit V, Migliorini D, Ranzanici G, Marinari E, Widmer V, Lobrinus JA, Momjian S, Costello J, Walker PR, Okada H, Weinschenk T, Herold-Mende C, Dietrich PY.

Oncoimmunology. 2017 Nov 7;7(2):e1391972. doi: 10.1080/2162402X.2017.1391972. eCollection 2018.

12.

Co-relation of overall survival with peripheral blood-based inflammatory biomarkers in advanced stage non-small cell lung cancer treated with anti-programmed cell death-1 therapy: results from a single institutional database.

Naqash AR, Stroud CRG, Butt MU, Dy GK, Hegde A, Muzaffar M, Yang LV, Hafiz M, Cherry CR, Walker PR.

Acta Oncol. 2018 Jun;57(6):867-872. doi: 10.1080/0284186X.2017.1415460. Epub 2017 Dec 15. No abstract available.

13.

Interleukin-6 as one of the potential mediators of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint blockade: evidence from a case report.

Naqash AR, Yang LV, Sanderlin EJ, Atwell DC, Walker PR.

Acta Oncol. 2018 May;57(5):705-708. doi: 10.1080/0284186X.2017.1406668. Epub 2017 Nov 24. No abstract available.

PMID:
29171332
14.

Identification of a novel population of highly cytotoxic c-Met-expressing CD8+ T lymphocytes.

Benkhoucha M, Molnarfi N, Kaya G, Belnoue E, Bjarnadóttir K, Dietrich PY, Walker PR, Martinvalet D, Derouazi M, Lalive PH.

EMBO Rep. 2017 Sep;18(9):1545-1558. doi: 10.15252/embr.201744075. Epub 2017 Jul 27.

15.

Local Radiotherapy Intensification for Locally Advanced Non-small-cell Lung Cancer - A Call to Arms.

Kalman NS, Weiss E, Walker PR, Rosenman JG.

Clin Lung Cancer. 2018 Jan;19(1):17-26. doi: 10.1016/j.cllc.2017.05.024. Epub 2017 Jun 16. Review.

PMID:
28712978
16.

Mechanistic Insight into Palladium-Catalyzed Cycloisomerization: A Combined Experimental and Theoretical Study.

Mekareeya A, Walker PR, Couce-Rios A, Campbell CD, Steven A, Paton RS, Anderson EA.

J Am Chem Soc. 2017 Jul 26;139(29):10104-10114. doi: 10.1021/jacs.7b05436. Epub 2017 Jul 12.

17.

[Brain tumor immunotherapy: Illusion or hope?]

Migliorini D, Dutoit V, Walker PR, Dietrich PY.

Bull Cancer. 2017 May;104(5):476-484. doi: 10.1016/j.bulcan.2017.01.014. Epub 2017 Mar 17. Review. French.

PMID:
28318492
18.

ER-mitochondria contacts control surface glycan expression and sensitivity to killer lymphocytes in glioma stem-like cells.

Bassoy EY, Kasahara A, Chiusolo V, Jacquemin G, Boydell E, Zamorano S, Riccadonna C, Pellegatta S, Hulo N, Dutoit V, Derouazi M, Dietrich PY, Walker PR, Martinvalet D.

EMBO J. 2017 Jun 1;36(11):1493-1512. doi: 10.15252/embj.201695429. Epub 2017 Mar 10.

19.

Hypoxia and antitumor CD8+ T cells: An incompatible alliance?

Vuillefroy de Silly R, Dietrich PY, Walker PR.

Oncoimmunology. 2016 Sep 9;5(12):e1232236. doi: 10.1080/2162402X.2016.1232236. eCollection 2016. Review.

20.

Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?

Dutoit V, Migliorini D, Dietrich PY, Walker PR.

Front Oncol. 2016 Dec 7;6:256. doi: 10.3389/fonc.2016.00256. eCollection 2016. Review.

21.

Decitabine Treatment of Glioma-Initiating Cells Enhances Immune Recognition and Killing.

Riccadonna C, Yacoub Maroun C, Vuillefroy de Silly R, Boehler M, Calvo Tardón M, Jueliger S, Taverna P, Barba L, Marinari E, Pellegatta S, Bassoy EY, Martinvalet D, Dietrich PY, Walker PR.

PLoS One. 2016 Aug 31;11(8):e0162105. doi: 10.1371/journal.pone.0162105. eCollection 2016.

22.

Failure patterns and survival outcomes in triple negative breast cancer (TNBC): a 15 year comparison of 448 non-Hispanic black and white women.

Prasad S, Efird JT, James SE, Walker PR, Zagar TM, Biswas T.

Springerplus. 2016 Jun 17;5(1):756. doi: 10.1186/s40064-016-2444-6. eCollection 2016.

23.

Enhancing Antitumor Immune Responses by Optimized Combinations of Cell-penetrating Peptide-based Vaccines and Adjuvants.

Belnoue E, Di Berardino-Besson W, Gaertner H, Carboni S, Dunand-Sauthier I, Cerini F, Suso-Inderberg EM, Wälchli S, König S, Salazar AM, Hartley O, Dietrich PY, Walker PR, Derouazi M.

Mol Ther. 2016 Sep;24(9):1675-85. doi: 10.1038/mt.2016.134. Epub 2016 Jul 5.

24.

Cell-penetrating peptides-the Swiss Army knife of cancer vaccines.

Walker PR, Belnoue E, Dietrich PY, Derouazi M.

Oncoimmunology. 2015 Dec 10;5(3):e1095435. eCollection 2016 Mar.

25.

Effects of community health interventions on under-5 mortality in rural Guinea-Bissau (EPICS): a cluster-randomised controlled trial.

Boone P, Elbourne D, Fazzio I, Fernandes S, Frost C, Jayanty C, King R, Mann V, Piaggio G, dos Santos A, Walker PR.

Lancet Glob Health. 2016 May;4(5):e328-35. doi: 10.1016/S2214-109X(16)30048-1.

26.

Glioma Stemlike Cells Enhance the Killing of Glioma Differentiated Cells by Cytotoxic Lymphocytes.

Bassoy EY, Chiusolo V, Jacquemin G, Riccadonna C, Walker PR, Martinvalet D.

PLoS One. 2016 Apr 13;11(4):e0153433. doi: 10.1371/journal.pone.0153433. eCollection 2016.

27.

Inflammatory TNBC Breast Cancer: Demography and Clinical Outcome in a Large Cohort of Patients With TNBC.

Biswas T, Efird JT, Prasad S, James SE, Walker PR, Zagar TM.

Clin Breast Cancer. 2016 Jun;16(3):212-6. doi: 10.1016/j.clbc.2016.02.004. Epub 2016 Feb 13.

PMID:
26988771
28.

Newly diagnosed lung cancer patients' preferences for and beliefs about physical activity prior to chemotherapy.

Karvinen KH, Vallance J, Walker PR.

Psychol Health Med. 2016 Jul;21(5):593-600. doi: 10.1080/13548506.2016.1139739. Epub 2016 Jan 27.

PMID:
26813963
29.

Immunotherapy of Brain Tumors.

Dutoit V, Migliorini D, Walker PR, Dietrich PY.

Prog Tumor Res. 2015;42:11-21. doi: 10.1159/000436986. Epub 2015 Sep 4. Review.

PMID:
26376741
30.

The CD40/CD40L axis in glioma progression and therapy.

Walker PR, Migliorini D.

Neuro Oncol. 2015 Nov;17(11):1428-30. doi: 10.1093/neuonc/nov138. Epub 2015 Jul 22. No abstract available.

31.

Ynamide carbopalladation: a flexible route to mono-, bi- and tricyclic azacycles.

Campbell CD, Greenaway RL, Holton OT, Walker PR, Chapman HA, Russell CA, Carr G, Thomson AL, Anderson EA.

Chemistry. 2015 Sep 1;21(36):12627-39. doi: 10.1002/chem.201501710. Epub 2015 Jul 16.

32.

Novel Cell-Penetrating Peptide-Based Vaccine Induces Robust CD4+ and CD8+ T Cell-Mediated Antitumor Immunity.

Derouazi M, Di Berardino-Besson W, Belnoue E, Hoepner S, Walther R, Benkhoucha M, Teta P, Dufour Y, Yacoub Maroun C, Salazar AM, Martinvalet D, Dietrich PY, Walker PR.

Cancer Res. 2015 Aug 1;75(15):3020-31. doi: 10.1158/0008-5472.CAN-14-3017. Epub 2015 Jun 26.

33.

Phenotypic switch of CD8(+) T cells reactivated under hypoxia toward IL-10 secreting, poorly proliferative effector cells.

Vuillefroy de Silly R, Ducimetière L, Yacoub Maroun C, Dietrich PY, Derouazi M, Walker PR.

Eur J Immunol. 2015 Aug;45(8):2263-75. doi: 10.1002/eji.201445284. Epub 2015 May 26.

34.

Weighing projections of physical decline in lung cancer surgery decisions.

Cykert S, Walker PR, Edwards LJ, McGuire FR, Dilworth-Anderson P.

Am J Med Sci. 2015 Jan;349(1):61-6. doi: 10.1097/MAJ.0000000000000354.

PMID:
25285513
35.

Immunotherapy for glioma: from illusion to realistic prospects?

Dietrich PY, Dutoit V, Walker PR.

Am Soc Clin Oncol Educ Book. 2014:51-9. doi: 10.14694/EdBook_AM.2014.34.51. Review.

36.

Effect of an exercise training intervention with resistance bands on blood cell counts during chemotherapy for lung cancer: a pilot randomized controlled trial.

Karvinen KH, Esposito D, Raedeke TD, Vick J, Walker PR.

Springerplus. 2014 Jan 8;3:15. doi: 10.1186/2193-1801-3-15. eCollection 2014.

37.

The neurotrophic hepatocyte growth factor attenuates CD8+ cytotoxic T-lymphocyte activity.

Benkhoucha M, Molnarfi N, Schneiter G, Walker PR, Lalive PH.

J Neuroinflammation. 2013 Dec 17;10:154. doi: 10.1186/1742-2094-10-154.

38.

Phase II study of low-dose paclitaxel with timed thoracic radiotherapy followed by adjuvant gemcitabine and carboplatin in unresectable stage III non-small cell lung cancer.

Zhang J, Gay HA, Russo S, Parent T, Aljumaily R, Walker PR.

Lung Cancer. 2014 Jan;83(1):67-72. doi: 10.1016/j.lungcan.2013.09.007. Epub 2013 Sep 25.

PMID:
24246506
39.

Getting by with a little help from the right CD4+ T cells.

Hoepner S, Walker PR.

Oncoimmunology. 2013 Sep 1;2(9):e25772. Epub 2013 Jul 29.

40.

Maximizing output from current glioma vaccine trials to construct robust next-generation immunotherapies.

Migliorini D, Dietrich PY, Walker PR.

Immunotherapy. 2013 Nov;5(11):1147-50. doi: 10.2217/imt.13.115. Review. No abstract available.

41.

Palladium- and ruthenium-catalyzed cycloisomerization of enynamides and enynhydrazides: a rapid approach to diverse azacyclic frameworks.

Walker PR, Campbell CD, Suleman A, Carr G, Anderson EA.

Angew Chem Int Ed Engl. 2013 Aug 26;52(35):9139-43. doi: 10.1002/anie.201304186. Epub 2013 Jul 15. No abstract available.

PMID:
23857937
42.

Synergy between CD8 T cells and Th1 or Th2 polarised CD4 T cells for adoptive immunotherapy of brain tumours.

Hoepner S, Loh JM, Riccadonna C, Derouazi M, Maroun CY, Dietrich PY, Walker PR.

PLoS One. 2013 May 23;8(5):e63933. doi: 10.1371/journal.pone.0063933. Print 2013.

43.

Dilated cardiomyopathy and skeletal myopathy: presenting features of a laminopathy.

Sims-Williams HP, Nye HJ, Walker PR.

BMJ Case Rep. 2013 Jan 17;2013. pii: bcr2012007574. doi: 10.1136/bcr-2012-007574.

44.

Involvement of NOS3 in RA-Induced neural differentiation of human NT2/D1 cells.

Jezierski A, Deb-Rinker P, Sodja C, Walker PR, Ly D, Haukenfrers J, Sandhu JK, Bani-Yaghoub M, Sikorska M.

J Neurosci Res. 2012 Dec;90(12):2362-77. doi: 10.1002/jnr.23118. Epub 2012 Sep 18.

PMID:
22987726
45.

Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy.

Dutoit V, Herold-Mende C, Hilf N, Schoor O, Beckhove P, Bucher J, Dorsch K, Flohr S, Fritsche J, Lewandrowski P, Lohr J, Rammensee HG, Stevanovic S, Trautwein C, Vass V, Walter S, Walker PR, Weinschenk T, Singh-Jasuja H, Dietrich PY.

Brain. 2012 Apr;135(Pt 4):1042-54. doi: 10.1093/brain/aws042. Epub 2012 Mar 14.

PMID:
22418738
46.

Physical activity promotion among oncology nurses.

Karvinen KH, McGourty S, Parent T, Walker PR.

Cancer Nurs. 2012 May-Jun;35(3):E41-8. doi: 10.1097/NCC.0b013e31822d9081.

PMID:
21946904
47.

Pulse interleukin-2 with famotidine induces CD56+ lymphocytes in the peripheral blood of patients with metastatic melanoma or kidney cancer.

Quan WD, Gagnon GA, Walker PR, Quan FM.

Cancer Biother Radiopharm. 2011 Feb;26(1):65-7. doi: 10.1089/cbr.2010.0879. Epub 2011 Feb 24.

PMID:
21348776
48.

T-cell immunotherapy for malignant glioma: toward a combined approach.

Dietrich PY, Dutoit V, Tran Thang NN, Walker PR.

Curr Opin Oncol. 2010 Nov;22(6):604-10. doi: 10.1097/CCO.0b013e32833dead8. Review.

PMID:
20739889
49.

Large-scale expression analysis reveals distinct microRNA profiles at different stages of human neurodevelopment.

Smith B, Treadwell J, Zhang D, Ly D, McKinnell I, Walker PR, Sikorska M.

PLoS One. 2010 Jun 15;5(6):e11109. doi: 10.1371/journal.pone.0011109.

50.

Immune infiltration of spontaneous mouse astrocytomas is dominated by immunosuppressive cells from early stages of tumor development.

Tran Thang NN, Derouazi M, Philippin G, Arcidiaco S, Di Berardino-Besson W, Masson F, Hoepner S, Riccadonna C, Burkhardt K, Guha A, Dietrich PY, Walker PR.

Cancer Res. 2010 Jun 15;70(12):4829-39. doi: 10.1158/0008-5472.CAN-09-3074. Epub 2010 May 25.

Supplemental Content

Loading ...
Support Center